Navigation Links
Femina Pharma Announces ALJ's Denial of Merck's Motion for Summary Determination on Domestic Industry in ITC Patent Dispute Concerning NuvaRing®
Date:11/28/2011

MIAMI, Nov. 28, 2011 /PRNewswire/ -- Femina Pharma Incorporated announces the issuance of Order 24 in Investigation No. 337-TA-768 (In the matter of Certain Vaginal Ring Birth Control Devices) by the Administrative Law Judge at the United States International Trade Commission ("ITC") denying the Merck Respondents' Motion for Summary Determination on the basis of lack of Domestic Industry.  The issuance of Order 24 follows the prior issuance on July 15, 2011 of Order 14 denying Merck's Motion for Summary Determination of Invalidity of U.S. Patent No. 6,086,909.  

On February 11, 2011, Femina Pharma Incorporated filed a complaint with the ITC for infringement of the '909 patent through importation of certain vaginal ring birth control devices, including NuvaRing® against Merck & Co., Inc., Schering Plough Corporation, Organon USA, Inc., N.V. Organon, Wal-Mart Stores, Inc., CVS Pharmacy, Inc., Walgreen Co. and several Canadian On-Line Pharmacies.  The Canadian On-Line Pharmacies have been held in default.  NuvaRing® was acquired by Merck through its 2009 acquisition of Schering Plough.

Separately, Femina Pharma Incorporated announces the November 15, 2011 filing of a patent infringement lawsuit in federal district court in the Eastern District of Virginia against Merck & Co., Inc., Schering Plough Corporation, Organon USA, Inc., Wal-Mart Stores, Inc., CVS Pharmacy, Inc. and Walgreen Co. alleging infringement of the '909 patent by the NuvaRing® (C.A. no. 1:11cv1248) (the "District Action").  The District Action seeks monetary damages and injunctive relief.

Joseph Matus Fuisz, CEO of Femina Pharma, stated: "We are pleased with the Order denying the Merck Respondents' Motion for Summary Determination on the basis of lack of Domestic Industry. Femina continues to exploit the claimed technology and has every right to seek redress at the ITC to protect US industry from infringing foreign imports.  Femina Pharma initiated Investigation No. 337-TA-768 to stop the unlawful importation of infringing product sold as NuvaRing®.  We look forward to the ITC hearing scheduled for January 2012.  Separately, we have initiated the District Action to seek monetary damages for current and past infringement."

Merck & Co., Inc., Schering Plough Corporation, Organon U.S.A., Inc., N.V. Organon, CVS Pharmacy, Inc., Wal-Mart Stores, Inc. and Walgreen Co.'s are represented in the ITC action by Covington & Burling, LLP. Femina Pharma Incorporated is represented in both the ITC and the District Action by The Fuisz-Kundu Group LLP (www.fuiszkundu.com).

About Femina Pharma Incorporated:

Femina Pharma Incorporated is a vaginal drug delivery company formed through the acquisition of the vaginal drug delivery assets of UMD Inc. Femina Pharma is managed by Joseph Fuisz and Richard C. Fuisz, M.D. (http://en.wikipedia.org/wiki/Richard_Carl_Fuisz). The Fuiszes have made substantial contributions in drug delivery including orally dissolving tablets and novel particle coating systems at Fuisz Technologies; inventing and developing thin film drug delivery technologies at Kosmos Pharma and MonoSol Rx, as well as independently developing extruded sheet technology, and have extensive experience working with big and specialty pharma (www.fuisz.com).

 


'/>"/>
SOURCE Femina Pharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. OncoSec to Present at 15th Annual Biotech and Specialty Pharmaceuticals Conference
2. ShangPharma to Attend Two Upcoming Investor Conferences
3. Pharmaceutical Packaging Industry - 2011 Yearbook
4. Inspiration Biopharmaceuticals Initiates Second Pivotal Clinical Study of Innovative Hemophilia Therapy OBI-1
5. Arena Pharmaceuticals to Present at the Piper Jaffray 23rd Annual Health Care Conference
6. Endo Pharmaceuticals to Present at the Bank of America Merrill Lynch 2011 Leveraged Finance Conference
7. Isis Pharmaceuticals to Present at the 23rd Annual Piper Jaffray Health Care Conference
8. AcelRx Pharmaceuticals to Present at the 23rd Annual Piper Jaffray Health Care Conference
9. PAREXEL Strengthens Late Phase and Observational Research Capabilities With Expert Team to Help Biopharma Meet Commercialization Goals
10. Questcor Pharmaceuticals to Present at the Piper Jaffray Healthcare Conference on November 30, 2011
11. Cadence Pharmaceuticals Announces Completion of Public Offering of Common Stock, Including Full Exercise of Over-Allotment Option by Underwriters
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Market - Forecast to 2022" report to their offering. ... method for the patients with kidney failure, it replaces the ... from the patient,s blood and thus the treatment helps to ... chloride in balance. Increasing number of ESRD ...
(Date:6/23/2016)... 2016 Roche (SIX: RO, ROG; OTCQX: RHHBY) ... Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated testing ... With this clearance, Roche is the first IVD company ... for sepsis risk assessment and management. PCT ... PCT levels in blood can aid clinicians in assessing ...
(Date:6/23/2016)... , June 23, 2016 Bracket , ... launch its next generation clinical outcomes platform, Bracket eCOA (SM) ... held on June 26 – 30, 2016 in ... first electronic Clinical Outcome Assessment product of its kind to ... #715. Bracket eCOA 6.0 is a flexible platform ...
Breaking Medicine Technology:
(Date:6/24/2016)... Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... surgery procedures that most people are unfamiliar with. The article goes on to state ... procedures, but also many of these less common operations such as calf and cheek ...
(Date:6/24/2016)... ... ... in a crisis. Her son James, eight, was out of control. Prone to extreme mood ... something upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a ... children and say he was going to kill them. If we were driving on ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, an ... Dr. Cheng has extensive experience with all areas of orthodontics, including robotic Suresmile ... orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can ...
(Date:6/24/2016)... ... , ... People across the U.S. are sharpening their pencils and honing their ... in which patients and their families pay tribute to a genetic counselor by nominating ... of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , In April, ...
(Date:6/24/2016)... ... 24, 2016 , ... Puradigm® & Innovative Solutions today announced ... and processing operations at its production facility, and opened its first two dispensaries ... manufacturer of a complete system of proactive air and surface purification solutions for ...
Breaking Medicine News(10 mins):